Navigation Links
SyntheMed Announces New Management Appointments
Date:10/2/2008

ISELIN, N.J., Oct. 2 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that Richard L. Franklin, MD, the company's Chairman, has assumed the newly-created position of Executive Chairman and Gere S. diZerega, MD, one of the company's clinical advisors, has assumed the newly-created position of Medical Director. In these consultancy roles, Dr. Franklin will be primarily involved with strategic planning, external communications and Board leadership whereas Dr. diZerega will focus on clinical and regulatory strategy and product planning. Robert P. Hickey, the company's President & CEO stated, "We are very fortunate that Rick and Gere have agreed to expand their involvement with our company and we look forward to benefiting from their experience and expertise."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products lead by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Completes $4.0 Million Equity Placement
2. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
3. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed Files Universal Shelf Registration
5. SyntheMed to Present at the Acumen BioFin Conference
6. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
7. Alba Therapeutics Corporation Announces Promotions
8. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
9. 23andMe Announces Breast Cancer Initiative
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DUBLIN , Feb 22, 2017 ... addition of the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, ... Forecasts (2016-2021)" report to their offering. ... Global Biological Crop Protection Market is ... The strong growth in biopesticide or biological crop protection ...
(Date:2/22/2017)... DIEGO , Feb. 22, 2017 Aethlon ... the results of a study that validated the ability ... that are associated with increased mortality in immune-suppressed sepsis ... patients. The objective of the study ... of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech consulting ... European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings ... after more than a decade with leading market research firm, GfK. He began ...
(Date:2/22/2017)... PARK, N.C., Feb. 22, 2017  United Therapeutics Corporation ... financial results for the fourth quarter and year ... financial results reflect continued growth as net revenues ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... ability to develop and advance our growing product ...
Breaking Biology Technology:
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
Breaking Biology News(10 mins):